Novartis wraps up Alcon with $12.9B deal
After almost a year of wrangling with recalcitrant minority shareholders, Novartis ($NVS) has wrapped up a deal to buy the rest of eye care company Alcon ($ACL). Novartis will still trade 2.8 shares of...
View ArticleNovartis CEO eyes growth strategies for Alcon
Novartis ($NVS) CEO Joe Jimenez (photo) told Reuters in an interview about his plans for the company's new eye-care division Alcon, which include broader use of implanted lenses and a larger presence...
View ArticleNovartis aims to beat $1.9B in cost savings by year's end
Novartis ($NVS) has two things to say. It now expects more bang for its buck from Alcon. The eye-care acquisition, which cost Novartis $51 billion, will deliver high single-digit to low double-digit...
View ArticleConsolidating admin ops in Fort Worth, Alcon asks for tax break
When M&A integration takes away in one place, it sometimes gives somewhere else. Witness Alcon, which is asking the city of Fort Worth, TX, for some tax breaks on a planned expansion that's...
View ArticleRecent Research Provides Formula for Timely Product Launch: Good Science +...
CHAPEL HILL, N.C., Oct. 24, 2011 /PRNewswire/ -- Two of the most crucial components of a successful new product launch application are good science and strong working relationships with the FDA....
View ArticleNovartis eye unit subpoenaed in U.S. probe
Novartis ($NVS) has disclosed a U.S. government probe into alleged healthcare fraud at its newly acquired eyecare unit Alcon, Reuters reports. The company received a subpoena from HHS, requesting...
View ArticleThromboGenics NV - Business Update
LEUVEN, Belgium, August 30, 2012 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today issued a business...
View ArticleClik here to view.
Novartis faces probes on Tekturna tactics, Iran sales
Novartis ($NVS) may be looking at another trial of its troubled blood pressure drug Tekturna. This would not be a clinical trial, however, but more of the civil or criminal kind.As The Wall Street...
View ArticleClik here to view.
Novartis' Jimenez says no need to sell Roche stake
Novartis CEO Joe JimenezWith a new chairman selected to take the helm of Novartis ($NVS), lots of folks are wondering what is in store for the Swiss drugmaker. Not so fast, CEO Joe Jimenez said this...
View ArticleNovartis nabs EU clearance for Jetrea; Roche's hep C drug Pegasys wins new use
Novartis ($NVS) won European approval for its eye drug Jetrea, as a treatment for vitreomacular traction, which can cause progressive and irreversible vision loss. The European Medicines Agency also...
View ArticleThromboGenics' JETREA® Available in Germany Public and Private Market
LEUVEN, Belgium, May 2, 2013 /PRNewswire/ --read more
View ArticleMinority Schering shareholders extract another €46 per share from Bayer
A group of minority Schering AG shareholders held out to the bitter end against what Bayer wanted to pay them for their shares, and they will now get the sweet deal they said they deserved.read more
View ArticleThromboGenics' JETREA® Launched in Denmark and Sweden
LEUVEN, Belgium, May 27, 2013 /PRNewswire/ --read more
View Article'Zorro' claims Novartis' Alcon unit faked trials to bribe Chinese docs
The bribery allegations in China just keep on coming. Novartis' Alcon eyecare division now says it will investigate claims it used fabricated clinical trials to bribe doctors. The news is none too...
View Article300 Novartis workers to be sacked when Alcon plant closes next year
Workers at the plant in Mississauga, Ontario, got the news that layoffs will begin in May and operations will wind down by the end of next year.
View Article
